Celgene Corporation (Nasdaq:CELG) today announced the National Cancer
Institute (NCI), a part of the National Institutes of Health, reported
initial data from a Phase III, randomized, double-blind, multi-center
clinical study led by the Cancer and Leukemia Group B (CALGB). The
investigational study evaluated REVLIMID® compared to placebo
in multiple myeloma patients following autologous stem cell transplant,
and the independent Data and Safety Monitoring Board reported that the
trial had met its primary endpoint of a statistically significant
improvement in time to disease progression. The study was sponsored by
the NCI under a Clinical Trials Agreement with Celgene.
Further results from the study will be presented in a peer-reviewed
setting in 2010.
Source Celgene Corporation